Lupin Receives Approval from U.S. FDA for Sildenafil for Oral Suspension

Mumbai, Baltimore, 24 March 2022: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Sildenafil for Oral Suspension, 10 mg/mL to market a generic...